Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: stijlemans b. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.
Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.
Romão E, Krasniqi A, Maes L, Vandenbrande C, Sterckx YG, Stijlemans B, Vincke C, Devoogdt N, Muyldermans S. Romão E, et al. Among authors: stijlemans b. Int J Mol Sci. 2020 Jan 2;21(1):310. doi: 10.3390/ijms21010310. Int J Mol Sci. 2020. PMID: 31906437 Free PMC article.
Immunogenicity Risk Profile of Nanobodies.
Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, Elkrim Y, Devoogdt N, Caveliers V, Lahoutte T, Muyldermans S, Breckpot K, Keyaerts M. Ackaert C, et al. Among authors: stijlemans b. Front Immunol. 2021 Mar 9;12:632687. doi: 10.3389/fimmu.2021.632687. eCollection 2021. Front Immunol. 2021. PMID: 33767701 Free PMC article.
A few good reasons to use nanobodies for cancer treatment.
Jumapili NA, Zivalj M, Barthelmess RM, Raes G, De Groof TWM, Devoogdt N, Stijlemans B, Vincke C, Van Ginderachter JA. Jumapili NA, et al. Among authors: stijlemans b. Eur J Immunol. 2023 Sep;53(9):e2250024. doi: 10.1002/eji.202250024. Epub 2023 Jun 27. Eur J Immunol. 2023. PMID: 37366246 Review.
M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment.
Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA, Laoui D. Van Overmeire E, et al. Among authors: stijlemans b. Cancer Res. 2016 Jan 1;76(1):35-42. doi: 10.1158/0008-5472.CAN-15-0869. Epub 2015 Nov 16. Cancer Res. 2016. PMID: 26573801
Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.
Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, Muyldermans S, Raes G, Bucala R, Vanlandschoot P, Van Ginderachter JA, Stijlemans B. Sparkes A, et al. Among authors: stijlemans b. FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25. FASEB J. 2018. PMID: 29401625 Free PMC article.
., Bucala, R., Vanlandschoot, P., Van Ginderachter, J. A., Stijlemans, B. Novel half-life extended anti-MIF nanobodies protect against endotoxic shock....
., Bucala, R., Vanlandschoot, P., Van Ginderachter, J. A., Stijlemans, B. Novel half-life extended anti-MIF nanobodies protect …
Generation of a nanobody targeting the paraflagellar rod protein of trypanosomes.
Obishakin E, Stijlemans B, Santi-Rocca J, Vandenberghe I, Devreese B, Muldermans S, Bastin P, Magez S. Obishakin E, et al. Among authors: stijlemans b. PLoS One. 2014 Dec 31;9(12):e115893. doi: 10.1371/journal.pone.0115893. eCollection 2014. PLoS One. 2014. PMID: 25551637 Free PMC article.
89 results